Noopept
Cognitive & MoodAlso known as: GVS-111, N-Phenylacetyl-L-prolylglycine Ethyl Ester, Ноопепт, Omberacetam
Mechanism
Noopept is one of the most popular nootropic peptides in the world, developed in Russia as a more potent successor to piracetam. It works by boosting levels of two critical brain growth factors — BDNF and NGF — which support learning, memory formation, and nerve cell health. Users typically notice improved memory recall, faster thinking, and better focus within days of starting it. It is roughly 1,000 times more potent by weight than piracetam, meaning effective doses are measured in milligrams rather than grams.
Technical detail
Noopept (ethyl ester of N-phenylacetyl-L-prolylglycine) is a synthetic dipeptide-like nootropic that acts as a prodrug — rapidly hydrolyzed in vivo to cycloprolylglycine, which crosses the blood-brain barrier. Primary mechanism involves upregulation of BDNF and NGF mRNA expression in rat hippocampus and cortex (Ostrovskaya et al., 2008). Modulates AMPA receptor trafficking, increasing GluR2/GluR3 subunit expression and enhancing glutamatergic neurotransmission without excitotoxicity. Inhibits delayed rectifier potassium channels, increasing neuronal excitability. Demonstrates neuroprotective effects against oxidative stress, calcium overload, and amyloid-beta toxicity in vitro. Inhibits stress-induced HPA axis hyperactivation. Anti-inflammatory effects via suppression of NF-kB and reduction of IL-6 and TNF-alpha in neuronal tissue. Active metabolite cycloprolylglycine also modulates endogenous anxiolytic systems.
Effects
NEUROLOGICAL: Primary target organ. Rapidly metabolized to cycloprolylglycine, the active CNS metabolite, which crosses the BBB within minutes of administration. Upregulates BDNF mRNA expression in rat hippocampus (CA1, CA3, dentate gyrus) — BDNF is the primary neurotrophin for synaptic plasticity, LTP (long-term potentiation), and memory consolidation (Ostrovskaya et al., 2008, PMID: 18819724). Upregulates NGF expression in hippocampus and cerebral cortex, supporting neuronal survival and cholinergic basal forebrain function. Modulates AMPA receptor trafficking — increases GluR2/GluR3 subunit expression, enhancing fast excitatory glutamatergic transmission without excitotoxicity (distinct from racetam mechanism). Inhibits delayed rectifier potassium channels, increasing neuronal excitability and action potential frequency. Neuroprotective: protects against oxidative stress (reduces lipid peroxidation, protein carbonylation), amyloid-beta(25-35) toxicity, and glutamate excitotoxicity in neuronal cultures. Increases alpha and beta1 EEG power (human data), associated with improved attention and cognitive processing. Anxiolytic effects — reduces anxiety in multiple animal models (elevated plus maze, Vogel conflict test) without sedation, possibly via modulation of endogenous anxiolytic peptide cycloprolylglycine. Improves both consolidation and retrieval phases of memory (passive avoidance, Morris water maze). IMMUNE: Anti-inflammatory in CNS tissue — reduces TNF-alpha, IL-6, and IL-1beta expression in activated microglia (in vitro). Suppresses NF-kB nuclear translocation in neuronal and glial cells. May modulate peripheral immune function via neuroimmune axis (limited data). CARDIOVASCULAR: Active metabolite cycloprolylglycine has been identified in stroke models — potential neuroprotection in cerebrovascular events (limited preclinical data). ENDOCRINE: No significant direct endocrine effects reported. Does not affect cortisol, testosterone, or thyroid hormones at standard doses. Mild cholinergic enhancement may marginally affect acetylcholine-mediated hormonal pathways. METABOLIC: Minimal metabolic effects. Rapidly absorbed orally (bioavailability ~99.7% in rats). Peak brain concentration within 7 minutes of oral dosing. Metabolized by hepatic peptidases to cycloprolylglycine. Negligible accumulation with repeated dosing. Tier 3: Consistently rated as one of the best nootropic peptides for memory enhancement in biohacker communities. User reports describe clearer thinking within 15-20 minutes of sublingual dosing, improved verbal fluency, and enhanced dream vividness. Some users report mild headache if choline intake is insufficient (shared with racetam class). Effects are described as "cleaner" than racetams with less tolerance development. Stacking with Semax or Selank is extremely popular in the nootropics community.
Practitioner Guide
DOSING TIPS: Oral: 10-30mg daily, typically divided into 2-3 doses. Start at 10mg/day and increase based on response. Sublingual: 10-20mg — faster onset (5-10 minutes vs. 15-20 minutes oral). Intranasal: Less common but effective at 5-10mg per dose (higher bioavailability via nasal route). Maximum recommended dose: 30mg/day in Russian prescribing guidelines. Take with food to reduce rare GI sensitivity. Morning and early afternoon dosing preferred — some users report sleep disruption at high doses taken late. RECONSTITUTION: N/A — sold as tablets (10mg), powder (for sublingual/nasal), or capsules. For sublingual: place powder or tablet under tongue, hold 1-2 minutes before swallowing. For nasal spray: some vendors sell pre-made nasal solutions. SUPPLEMENT SYNERGIES: Choline source is strongly recommended — Alpha-GPC (300-600mg) or CDP-Choline (250-500mg) prevents headaches and enhances cholinergic potentiation. Stack with Semax or NA-Semax-Amidate for synergistic BDNF upregulation (different mechanisms — Noopept via transcription, Semax via TrkB sensitivity). Selank or NA-Selank-Amidate for added anxiolysis + cognitive enhancement. Bacopa monnieri (300mg standardized extract) for complementary memory support. Lion's Mane mushroom (500-1000mg) for additional NGF upregulation. Omega-3s (2-4g/day EPA+DHA) support membrane fluidity needed for AMPA receptor trafficking. CYCLING: Russian guidelines: courses of 1.5-3 months with 1-month breaks. Many practitioners recommend 8-12 weeks on, 4 weeks off. Tolerance is less of an issue than with racetams but can develop with uninterrupted long-term use. Some users successfully take Noopept continuously for months without tolerance at moderate doses (10-20mg/day). STACKING: Ultimate nootropic stack: Noopept + Semax + Selank (the "Russian stack"). Cognitive recovery: Noopept + Cerebrolysin + Lion's Mane. Focus stack: Noopept + Alpha-GPC + caffeine + L-theanine. Memory stack: Noopept + Bacopa + phosphatidylserine. CONTRAINDICATION NUANCES: Patients with hypertension should monitor BP — some reports of transient BP elevation at higher doses. Avoid combining with other strong glutamatergic compounds (risk of excitotoxicity at very high doses). May potentiate stimulant effects — reduce caffeine/amphetamine doses if combining. Pregnancy/breastfeeding — no safety data, avoid. Patients with schizophrenia or psychotic disorders — enhanced glutamatergic transmission may theoretically worsen positive symptoms (no case reports, theoretical). Hepatic impairment — use lower doses (hepatic metabolism). STORAGE: Tablets/capsules — room temperature, protect from moisture. Powder — keep desiccated, cool, dark. Stable at room temperature for 3+ years (tablets). PATIENT EDUCATION: This is Russia's most popular nootropic — approved there as a prescription drug since 1996. It is roughly 1,000x more potent by weight than piracetam but works by a different mechanism. Effects are subtle but cumulative — expect improved verbal recall, faster word-finding, and sharper focus over 1-2 weeks. Not a stimulant — it will not make you "wired" or anxious. Take it with a choline source (like Alpha-GPC) or you may get headaches. It is legal to purchase and possess in the US and most countries (unscheduled), but it is NOT FDA-approved.
Research Summary
TIER 1 (Gold Standard): Ostrovskaya et al., 2008 — Noopept stimulates expression of NGF and BDNF in rat hippocampus (PMID: 18819724, Bulletin of Experimental Biology and Medicine). Russian State Pharmacopoeia monograph and prescribing information (approved nootropic). Boiko et al., 2000 — Clinical study demonstrating cognitive improvement in patients with organic brain disorders (Russian peer-reviewed). TIER 2 (Strong): Ostrovskaya et al., 2014 — Neuroprotective effects against amyloid toxicity (PMID: 24782037). Gudasheva et al. — Cycloprolylglycine as endogenous anxiolytic (multiple publications from Zakusov Institute). Jia et al., 2011 — Noopept prevents oxidative stress-induced cognitive impairment (PMID: 22107885). Examine.com comprehensive evidence review — moderate-quality evidence for cognition. Multiple animal studies confirming memory enhancement in passive avoidance, Morris water maze, and conditioned avoidance paradigms. Pharmacokinetic data: oral bioavailability 99.7% (rats), peak brain concentration 7 minutes, T1/2 38 minutes. TIER 3 (Moderate): Extensive community evidence from Reddit r/nootropics, Longecity, and biohacker forums. Consistently ranked among top 5 nootropic peptides globally. International use data — popular in Russia, EU, and US nootropics markets. Practitioner protocols from nootropics-focused clinics. DrugBank entry (DB12023). KEY FINDINGS: (1) BDNF and NGF upregulation is well-documented and clinically relevant. (2) AMPA receptor modulation is a unique mechanism among nootropics. (3) Approved in Russia with decades of clinical use data. (4) Anxiolytic + cognitive enhancing profile is unusual and clinically valuable. (5) Safety profile is excellent — very few adverse effects in decades of use. GAPS: No large-scale Western RCTs. Optimal chronic dosing undefined. Long-term safety beyond Russian post-marketing data. Mechanism of anxiolysis not fully elucidated. ACTIVE TRIALS: No active trials on ClinicalTrials.gov for Noopept/GVS-111. Some studies ongoing for cycloprolylglycine (active metabolite).